ZTS

Zoetis Inc.

HealthcareDrug Manufacturers - Specialty & GenericNASDAQ

$116.63

-$0.72 (-0.61%)today

Conviction

0/ 10

Fair Value$151

Upside+29.47%

Signal0

Market Cap$51.3B

52W Range$113.29–$172.23

Next EarningsMay 5

Price History

FAIR VALUE ANALYSISMonte Carlo · 3,000 runs · 99% valid

Fair Value$77.66

Current Price$118.15

Upside / Down-34.3%

P(Undervalued)0.8%

P(20%+ Up)0.0%

P(15%+ Down)90.8%

Fair Value Distribution — percentile bands

0.8% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

12.7%/yr

±4.1% · revenue growth to justify current price

FCF-Based Reverse DCF

12.8%/yr

±3.0% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

KEY VALUE DRIVERS

Spearman correlation — what moves this valuation most

Quick Take

Zoetis Inc.

Trailing P/E19.3x

Forward P/E15.4x

P/S5.4x

EPS (TTM)$6.02

Analyst Target$151

Analyst Upside29.5%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kMar 2

Conviction: unchanged

ZTS 2025 10-K: Diversified Growth Platform with Patent Headwinds

Zoetis 2025 revenue .35B (U.S. 54%, Intl 45%). Patent cliff 2025-27 (Draxxin, Cerenia), dependent on lifecycle innovation fill. R&D up 2% to M. Companion animals 70% of revenue (resilient); livestock ...